- Home
- / Akari Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Akari Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.5
2024-10-29
Market Capitalization
$30.4 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 2.2M | 2.3M | 3.8M | 5.5M | 9.9M | 11.8M | 10.9M | 8.2M | 9.2M | 8.1M | 13.5M | 11.4M | 9.7M | 9.3M |
| Operating expense total | 3.7M | 3.6M | 10.2M | 11.3M | 27.2M | 35.1M | 22.7M | 17.0M | 23.1M | 16.8M | 16.6M | 12.1M | ||
| EBIT | (3.7M) | (3.6M) | (10.2M) | (30.6M) | (27.2M) | (37.8M) | (20.0M) | (17.0M) | (18.0M) | (17.2M) | (23.1M) | (16.8M) | (21.6M) | (17.3M) |
| Interest income | 440.0K | 270.0K | 549.0K | 20.7K | 143.2K | 175.4K | 222.3K | 5.5K | 13.6K | 10.6K | 45.9K | 82.0K | 8.0K | 1.0K |
| Interest expense | 3.1M | 143.0K | ||||||||||||
| Pre tax profit | (45.3M) | (18.1M) | (35.4M) | (16.5M) | (17.1M) | (17.1M) | (17.4M) | (17.7M) | (10.0K) | (19.8M) | (18.3M) | |||
| Income tax expense | (1.0M) | |||||||||||||
| Net Income | (4.3M) | (3.6M) | (9.6M) | (45.3M) | (18.1M) | (35.4M) | (16.5M) | (17.1M) | (17.1M) | (17.4M) | (17.7M) | (10.0M) | (19.8M) | (17.3M) |